{"schema_version":"secwatch.filing_event.v1","accession":"0000950142-22-002339","form_type":"8-K","ticker":"NRXP","cik":"0001719406","company_name":"NRX Pharmaceuticals, Inc.","filed_at":"2022-07-28T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.777778+00:00","generated_at":"2026-06-24T07:36:57.194391+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"negative","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"NRx Pharmaceuticals Chief Corporate Officer, General Counsel & Corporate Secretary resigns effective July 22, 2022","bullets":["Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary, effective July 22, 2022.","Resignation not due to any disagreement with management or board regarding operations, policies, or practices.","Ms. Daigneault left to pursue other personal and professional interests.","No successor named in the filing."],"urls":{"canonical":"https://secwatch.observer/filing/0000950142-22-002339","json":"https://secwatch.observer/filing/0000950142-22-002339.json","markdown":"https://secwatch.observer/filing/0000950142-22-002339.md","text":"https://secwatch.observer/filing/0000950142-22-002339.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/0000950142-22-002339-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/eh220274812_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T07:36:57.194391+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a23f66f419","claim":"Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary at NRX Pharmaceuticals, Inc..","evidence_excerpt":"On July 22, 2022, Ms. Alessandra Daigneault resigned as Chief Corporate Officer, General Counsel and Corporate Secretary of NRx Pharmaceuticals, Inc. (the “Company”), effective immediately.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1719406/000095014222002339/0000950142-22-002339-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Chief Corporate Officer, General Counsel and Corporate Secretary"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}